Experts call for new frameworks for personalized mRNA cancer vaccines

Experts call for new frameworks for personalized mRNA cancer vaccines

商业 健康
登录后即可置顶此事件

STAT reported that, after the Phase 3 trial of the personalized mRNA vaccine intismeran demonstrated a 42% cut in melanoma recurrence or death risk compared with pembrolizumab, experts called for new regulatory pathways, integrated delivery models and payment structures to broaden patient access in the United States. Moderna and Merck announced the trial results, noting the vaccine combined with Keytruda reduced distant metastasis risk by 38% and met study expectations.

The announcement triggered a drop in both companies' shares. Later, Moderna chief executive Stéphane Bancel said the data would shape the company's future research agenda.

参与者

Moderna Merck TD Cowen RBC Capital Markets

地点

Wall Street, New York, United States

事实核查

这些指标如何工作
总体结论: 部分 置信度: 56% 声明: 2
摘要

Two claims stating that a Merck-Moderna personalized mRNA vaccine combined with Keytruda reduced the risk of death or recurrence by 42% in melanoma patients were partially confirmed, though some details like exact dates or study descriptions were not fully verified. One claim about a phase III study on October 23, 2026, reporting the same 42% reduction did not have enough evidence to be confirmed.

登录或订阅以查看完整分析，包括声明、来源和时间线验证。

注册 登录

本部分包含基于外部来源的自动化断言核查，可能存在不准确之处。

文章

2026年十月27日
1 篇总计
How to get cancer vaccines to patients
How to get cancer vaccines to patients

STAT • 10月27日 08:33

A Phase 3 trial showed the mRNA cancer vaccine intismeran autogene cut recurrence or death risk by 42% versus pembrolizumab, prompting experts to call for new regulatory pathways, integrated delivery models and payment structures to broaden patient access.

可信度 72% 操纵 12% 中立
2026年十月26日
2 篇总计
Moderna CEO on what's next after success in cancer vaccine
Moderna CEO on what's next after success in cancer vaccine

STAT • 10月26日 08:31

Moderna's chief executive Stéphane Bancel highlighted the upcoming presentation of Phase 3 results for the mRNA melanoma therapy intismeran and outlined its implications for the company's research direction.

可信度 72% 操纵 8% 中立
World-First Cancer Vaccine Cuts Melanoma Recurrence or Death Risk by 42% in Landmark Trial
World-First Cancer Vaccine Cuts Melanoma Recurrence or Death Risk by 42% in Landmark Trial

ScienceAlert • 10月26日 02:01

A phase 3 study of a personalized mRNA vaccine developed by Moderna and Merck showed a 42% reduction in melanoma recurrence or death compared with standard immunotherapy alone.

可信度 78% 操纵 32% 中立
2026年十月25日
2 篇总计
Cancer vaccine significantly reduces chance of melanoma patients’ tumours returning, results show
Cancer vaccine significantly reduces chance of melanoma patients’ tumours returning, results show

The Globe and Mail • 10月25日 18:12

A trial of the mRNA-based vaccine intismeran showed a 42% reduction in melanoma recurrence two years after surgery when added to standard therapy.

可信度 78% 操纵 12% 中立
What's next for cancer vaccines after successful melanoma study
What's next for cancer vaccines after successful melanoma study

STAT • 10月25日 08:34

A Merck-Moderna mRNA vaccine combined with Keytruda lowered melanoma recurrence or death by 42% in a pivotal study, prompting discussion of broader cancer-vaccine applications.

可信度 73% 操纵 32% 中立
2026年十月23日
1 篇总计
Personalized mRNA vaccine for melanoma cut risk of cancer’s return in late-stage trial
Personalized mRNA vaccine for melanoma cut risk of cancer’s return in late-stage trial

NBC News • 10月23日 18:42

In a phase III study, the Moderna-Merck personalized mRNA vaccine intismeran reduced melanoma recurrence and death by 42% when added to Keytruda, compared with Keytruda alone.

可信度 71% 操纵 32% 中立
2026年十月22日
2 篇总计
Moderna, Merck shares fall on eagerly anticipated cancer vaccine results
Moderna, Merck shares fall on eagerly anticipated cancer vaccine results

BioPharma Dive • 10月22日 22:24

A combined vaccine and Keytruda regimen reduced the relative risk of disease recurrence or death by 42% in advanced melanoma, meeting expectations, while the companies' stocks fell after the announcement.

可信度 71% 操纵 8% 中立
Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%

Ars Technica • 10月22日 22:12

Merck and Moderna reported that their personalized mRNA vaccine combined with Keytruda reduced the risk of death or recurrence by 42% in patients with resected melanoma, and lowered distant metastasis risk by 38%.

可信度 78% 操纵 7% 中立

相关事件